TY - JOUR
T1 - Senescence-associated reprogramming promotes cancer stemness
AU - Milanovic, Maja
AU - Fan, Dorothy N.Y.
AU - Belenki, Dimitri
AU - Däbritz, J. Henry M.
AU - Zhao, Zhen
AU - Yu, Yong
AU - Dörr, Jan R.
AU - Dimitrova, Lora
AU - Lenze, Dido
AU - Monteiro Barbosa, Ines A.
AU - Mendoza-Parra, Marco A.
AU - Kanashova, Tamara
AU - Metzner, Marlen
AU - Pardon, Katharina
AU - Reimann, Maurice
AU - Trumpp, Andreas
AU - Dörken, Bernd
AU - Zuber, Johannes
AU - Gronemeyer, Hinrich
AU - Hummel, Michael
AU - Dittmar, Gunnar
AU - Lee, Soyoung
AU - Schmitt, Clemens A.
N1 - Funding Information:
Acknowledgements We thank G. Evan, the late A. Harris, T. Jacks and T. Jenuwein for mice, cells and materials; E. Berg, N. Burbach, A. Herrmann, H. Lammert, S. Mende, B. Teichmann and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) flow cytometry laboratory for technical assistance; and members of the Schmitt laboratory for discussions and editorial advice. This work was supported by a Ph.D. fellowship to J.R.D. from the Boehringer Ingelheim Foundation; by grants from the Deutsche Forschungsgemeinschaft to B.D., M.H. and C.A.S. (SFB/TRR 54) and to A.T. (SFB 873); by the Helmholtz Alliance ‘Preclinical Comprehensive Cancer Center’ grant (HA-305) from the Helmholtz Association to A.T. and C.A.S.; by the Dietmar Hopp Foundation to A.T.; and by the Deutsche Krebshilfe (grant 110678) to C.A.S. This interdisciplinary work was further made possible by the Berlin School of Integrative Oncology (BSIO) graduate program funded within the German Excellence Initiative, and the German Cancer Consortium (GCC).
Publisher Copyright:
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
PY - 2018/1/4
Y1 - 2018/1/4
N2 - Cellular senescence is a stress-responsive cell-cycle arrest program that terminates the further expansion of (pre-)malignant cells. Key signalling components of the senescence machinery, such as p16 INK4a, p21 CIP1 and p53, as well as trimethylation of lysine 9 at histone H3 (H3K9me3), also operate as critical regulators of stem-cell functions (which are collectively termed 'stemness'). In cancer cells, a gain of stemness may have profound implications for tumour aggressiveness and clinical outcome. Here we investigated whether chemotherapy-induced senescence could change stem-cell-related properties of malignant cells. Gene expression and functional analyses comparing senescent and non-senescent B-cell lymphomas from Eμ-Myc transgenic mice revealed substantial upregulation of an adult tissue stem-cell signature, activated Wnt signalling, and distinct stem-cell markers in senescence. Using genetically switchable models of senescence targeting H3K9me3 or p53 to mimic spontaneous escape from the arrested condition, we found that cells released from senescence re-entered the cell cycle with strongly enhanced and Wnt-dependent clonogenic growth potential compared to virtually identical populations that had been equally exposed to chemotherapy but had never been senescent. In vivo, these previously senescent cells presented with a much higher tumour initiation potential. Notably, the temporary enforcement of senescence in p53-regulatable models of acute lymphoblastic leukaemia and acute myeloid leukaemia was found to reprogram non-stem bulk leukaemia cells into self-renewing, leukaemia-initiating stem cells. Our data, which are further supported by consistent results in human cancer cell lines and primary samples of human haematological malignancies, reveal that senescence-associated stemness is an unexpected, cell-autonomous feature that exerts its detrimental, highly aggressive growth potential upon escape from cell-cycle blockade, and is enriched in relapse tumours. These findings have profound implications for cancer therapy, and provide new mechanistic insights into the plasticity of cancer cells.
AB - Cellular senescence is a stress-responsive cell-cycle arrest program that terminates the further expansion of (pre-)malignant cells. Key signalling components of the senescence machinery, such as p16 INK4a, p21 CIP1 and p53, as well as trimethylation of lysine 9 at histone H3 (H3K9me3), also operate as critical regulators of stem-cell functions (which are collectively termed 'stemness'). In cancer cells, a gain of stemness may have profound implications for tumour aggressiveness and clinical outcome. Here we investigated whether chemotherapy-induced senescence could change stem-cell-related properties of malignant cells. Gene expression and functional analyses comparing senescent and non-senescent B-cell lymphomas from Eμ-Myc transgenic mice revealed substantial upregulation of an adult tissue stem-cell signature, activated Wnt signalling, and distinct stem-cell markers in senescence. Using genetically switchable models of senescence targeting H3K9me3 or p53 to mimic spontaneous escape from the arrested condition, we found that cells released from senescence re-entered the cell cycle with strongly enhanced and Wnt-dependent clonogenic growth potential compared to virtually identical populations that had been equally exposed to chemotherapy but had never been senescent. In vivo, these previously senescent cells presented with a much higher tumour initiation potential. Notably, the temporary enforcement of senescence in p53-regulatable models of acute lymphoblastic leukaemia and acute myeloid leukaemia was found to reprogram non-stem bulk leukaemia cells into self-renewing, leukaemia-initiating stem cells. Our data, which are further supported by consistent results in human cancer cell lines and primary samples of human haematological malignancies, reveal that senescence-associated stemness is an unexpected, cell-autonomous feature that exerts its detrimental, highly aggressive growth potential upon escape from cell-cycle blockade, and is enriched in relapse tumours. These findings have profound implications for cancer therapy, and provide new mechanistic insights into the plasticity of cancer cells.
UR - http://www.scopus.com/inward/record.url?scp=85040200652&partnerID=8YFLogxK
U2 - 10.1038/nature25167
DO - 10.1038/nature25167
M3 - Article
C2 - 29258294
AN - SCOPUS:85040200652
VL - 553
SP - 96
EP - 100
JO - Nature
JF - Nature
SN - 0028-0836
IS - 7686
ER -